FDA grants Fast-Track status for Relmada’s major depressive disorder therapy
In a Phase II trial, REL-1017 was found to offer quick and long-lasting antidepressant effects.
mental health conditions
Latest in
mental health conditions
Alto Neuroscience uses AI to create biomarkers for personalised mental health drugs
GlobalData’s Drugs Database reveals that more than 490 unique drugs have been discovered using AI-based technologies.
By
Mental health disorder rates in the workplace are soaring
According to Mental Health, 14.7% of individuals develop mental health disorders in the workplace, a trend increased by Covid-19.
By
FDA accepts Teva-MedinCell’s new drug application for schizophrenia drug
The application is supported by data from two Phase III clinical trials of TV46000 in schizophrenia patients aged 13 to…
Maternal smoking as potential risk factor for Tourette syndrome among children
Data from recent studies reinforce the evidence that suggests maternal smoking during pregnancy is a risk factor for Tourette syndrome.
By
FDA approves Alkermes’ Lybalvi for schizophrenia treatment
FDA has granted approval for Alkermes’ Lybalvi for treating schizophrenia in adults and helping with bipolar I disorder.
Major depressive disorder: why does it affect women more?
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it…
By
Novartis to acquire neuroscience firm Cadent Therapeutics for up to $770m
Novartis has entered into a definitive agreement to acquire all of the outstanding capital stock of US-based neuroscience company Cadent…